Elise S. Bales

Biochemistry, Genetics and Molecular Biology · Life Sciences

30h-index3.6kcitations135works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

S100 Proteins and Annexins(59), Melanoma and MAPK Pathways(50), Lipid metabolism and biosynthesis(17), Protease and Inhibitor Mechanisms(16), Mechanisms of cancer metastasis(14)

Publications135 total

Table S2 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2
2025Open Access
Figure S7 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2
2025Open Access
Figure S2 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2
2025Open Access
Table S1 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2
2025Open Access
Figure S6 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2
2025Open Access
Figure S3 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2
2025Open Access
Figure S5 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2
2025Open Access
Figure S1 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2
2025Open Access
Figure S4 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2
2025Open Access
Figure S8 from Fibronectin Contributes to a BRAF Inhibitor–driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2
2025Open Access
Table S1 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.
2024Open Access
Figure S4 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.
2024Open Access
Figure S2 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.
2024Open Access
Figure S6 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.
2024Open Access
Figure S1 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.
2024Open Access
Figure S8 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.
2024Open Access
Figure S5 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.
2024Open Access
Figure S7 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.
2024Open Access
Figure S6 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.
2024Open Access
Figure S4 from Fibronectin contributes to a BRAF inhibitor-driven invasive phenotype in thyroid cancer through EGR1, which can be blocked by inhibition of ERK1/2.
2024Open Access
page 1 of 7Next →

Frequent Co-authors

David J. Orlicky(20), James L. McManaman(16), Paul S. MacLean(6), Estela E. Medrano(6), Jenifer Monks(6), Ramón A. Lorca(6), Colleen G. Julian(6), Lorna G. Moore(6), Matthew R. Jackman(5), Joshua Johnson(5), Debdutta Bandyopadhyay(4), Andrew E. Libby(4), Honnavara N. Ananthaswamy(4), Leonard H. Goldberg(4), Sydney L. Lane(4), Julie A. Houck(4), Miguel A. Lanaspa(3), Christina Cicerchi(3), Carlos A. Roncal-Jiménez(3), Richard J. Johnson(3)